Filing Details

Accession Number:
0001447348-12-000025
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-05-03 11:25:41
Reporting Period:
2012-05-01
Filing Date:
2012-05-03
Accepted Time:
2012-05-03 11:25:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
835887 Progenics Pharmaceuticals Inc PGNX Pharmaceutical Preparations (2834) 133379479
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250274 J Robert Israel 777 Old Saw Mill River Road
Tarrytown NY 10591
Senior Vp Medical Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-05-01 1,000 $5.33 39,383 No 4 M Direct
Common Stock Disposition 2012-05-01 1,000 $10.93 38,383 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2012-05-01 1,000 $10.93 1,000 $5.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,000 2010-07-01 2019-07-01 No 4 M Direct
Footnotes
  1. The Reporting Person is exercising options under this grant in pre-established increments under and in accordance with provisions of a previously established Plan of Sale under Rule 10b5-1, which was established in accordance with the policies and procedures of the Issuer.
  2. This transaction was executed in multiple trades at various price ranges. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. The stock options become exercisable in three equal annual installments, commencing one year from the grant date.